BVF Partners Amends Kymera Therapeutics Stake, Signals Ownership Shift

TL;DR

**BVF Partners just updated its Kymera Therapeutics stake, watch for potential market reaction!**

AI Summary

BVF Partners L.P., a significant shareholder in Kymera Therapeutics, Inc., filed an Amendment No. 4 to its Schedule 13D on January 9, 2024, indicating a change in their beneficial ownership. The filing, triggered by an event on January 5, 2024, updates their position in Kymera's Common Stock, par value $0.0001 per share. This matters to investors because changes in ownership by large institutional investors like BVF Partners can signal their evolving sentiment about the company's future prospects, potentially influencing stock price movements.

Why It Matters

This filing shows a major institutional investor, BVF Partners, has updated its stake in Kymera Therapeutics, which can influence market perception and investor confidence.

Risk Assessment

Risk Level: medium — Changes in significant institutional ownership can create volatility, but this filing alone doesn't detail the nature of the change (increase or decrease), making the immediate impact uncertain.

Analyst Insight

Investors should monitor subsequent filings from BVF Partners L.P. to understand the specific nature of the change in their ownership (e.g., buying or selling shares) and assess its potential impact on Kymera Therapeutics' stock price.

Key Numbers

• $0.0001 — Par Value per Share (The stated par value of Kymera Therapeutics' Common Stock.)

Key Players & Entities

• Kymera Therapeutics, Inc. (company) — the subject company of the filing
• BVF Partners L.P. (company) — the reporting person filing the amendment
• James Kratky (person) — authorized to receive notices for BVF Partners L.P.
• $0.0001 (dollar_amount) — par value per share of Kymera's Common Stock
• January 5, 2024 (date) — date of the event requiring the filing
• January 9, 2024 (date) — date the amendment was filed

Forward-Looking Statements

• BVF Partners L.P. will continue to be an active shareholder in Kymera Therapeutics, Inc. (BVF Partners L.P.) — high confidence, target: Q2 2024

FAQ

Key Financial Figures

• $0.0001 — Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class o
• $57,393,095 — eficially owned by BVF is approximately $57,393,095, including brokerage commissions. The a
• $13,898,176 — dquo;Offering”), is approximately $13,898,176. The aggregate purchase price of the 2
• $44,181,738 — ficially owned by BVF2 is approximately $44,181,738, including brokerage commissions. The a
• $9,490,326 — uired in the Offering, is approximately $9,490,326. The aggregate purchase price of the 2
• $5,346,778 — ned by Trading Fund OS is approximately $5,346,778, including brokerage commissions. The a
• $1,331,503 — uired in the Offering, is approximately $1,331,503. The aggregate purchase price of the 1
• $1,876,596 — rtners Managed Account is approximately $1,876,596, including brokerage commissions. The a
• $279,895 — uired in the Offering, is approximately $279,895. Stock options held by Mr. Hrustanovic

Filing Documents

• sc13da407422kymr_01092024.htm (SC 13D/A) — 310KB
• 0000921895-24-000070.txt ( ) — 312KB

Source and Amount of Funds or Other Consideration

Item 3. Source and Amount of Funds or Other Consideration .

is hereby amended

Item 3 is hereby amended and restated to read as follows: The Shares beneficially owned by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Account were purchased with working capital (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business) in open market purchases, except as otherwise noted. The aggregate purchase price of the 2,656,191 Shares directly beneficially owned by BVF is approximately $57,393,095, including brokerage commissions. The aggregate purchase price of the 550,425 pre-funded warrants (the “Pre-Funded Warrants”) owned by BVF, which BVF acquired in the Issuer’s public offering priced on January 5, 2024 (the “Offering”), is approximately $13,898,176. The aggregate purchase price of the 2,104,075 Shares directly beneficially owned by BVF2 is approximately $44,181,738, including brokerage commissions. The aggregate purchase price of the 375,856 Pre-Funded Warrants owned by BVF2, which BVF2 acquired in the Offering, is approximately $9,490,326. The aggregate purchase price of the 294,632 Shares directly beneficially owned by Trading Fund OS is approximately $5,346,778, including brokerage commissions. The aggregate purchase price of the 52,733 Pre-Funded Warrants owned by Trading Fund OS, which Trading Fund OS acquired in the Offering, is approximately $1,331,503. The aggregate purchase price of the 106,903 Shares held in the Partners Managed Account is approximately $1,876,596, including brokerage commissions. The aggregate purchase price of the 11,085 Pre-Funded Warrants held in the Partners Managed Account, which the Partners Managed Account acquired in the Offering, is approximately $279,895. Stock options held by Mr. Hrustanovic referencing 40,127 Shares, 20,063 Shares, 12,000 Shares and 12,000 Shares, 72,190 Shares of which Mr. Hrustanovic may be deemed to beneficially own, were awarded to him on August 20, 2020, June 16, 2021, June 15, 2022 a

Interest in Securities of the Issuer

Item 5. Interest in Securities of the Issuer . Items 5(a) – (c) are hereby amended and restated to read as follows: (a) The aggregate percentage of Shares reported owned by each person named herein is based upon a denominator that is the sum of: (i) 57,700,734 Shares outstanding as of January 9, 2024, which is the total number of Shares outstanding following the closing of the Offering as reported in the Issuer’s prospectus supplement on Form 424B5 filed with the Securities and Exchange Commission on January 5, 2024 (the “Prospectus Supplement”), and (ii) certain or all of the 669,370 Shares underlying the Pre-Funded Warrants held by the Reporting Persons that are currently exercisable, as applicable. 13 CUSIP No. 501575104 As of the date hereof, (i) BVF beneficially owned 3,206,616 Shares, including 550,425 Shares underlying 550,425 Pre-Funded Warrants held by it that are currently exercisable, representing percentage ownership of approximately 5.5% of the Shares outstanding, (ii) BVF2 beneficially owned 2,223,020 Shares, including 118,945 Shares underlying 118,945 Pre-Funded Warrants held by it that are currently exercisable and excluding 256,911 Shares underlying 256,911 Pre-Funded Warrants held by it that are not exercisable due to the Warrants Blocker (as defined below), representing percentage ownership of approximately 3.8% of the Shares outstanding, (iii) Trading Fund OS beneficially owned 294,632 Shares, excluding 52,733 Shares underlying 52,733 Pre-Funded Warrants held by it that are not exercisable due to the Warrants Blocker, representing percentage Shares underlying 11,085 Pre-Funded Warrants held by it that are not exercisable due to the Warrants Blocker, representing percentage BVF GP, as the general partner of BVF, may be deemed to

Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer

Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer .

is hereby amended

Item 6 is hereby amended to add the following: Stock options referencing 12,000 Shares were awarded to Mr. Hrustanovic on June 15, 2023 for no consideration in connection with his service on the Board. Pursuant to a certain agreement entered into between Partners and Mr. Hrustanovic, Mr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the Shares issuable upon exercise of the above referenced stock options to Partners. Such stock options shall vest in full upon the earlier to occur of (i) June 15, 2024 and (ii) the date of the next annual meeting of the Issuer's stockholders. 15 CUSIP No. 501575104

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct. Dated: January 9, 2024 BIOTECHNOLOGY VALUE FUND, L.P. BIOTECHNOLOGY VALUE TRADING FUND OS LP By: BVF I GP LLC, its general partner By: BVF Partners L.P., its investment manager By: BVF Inc., its general partner By: /s/ Mark N. Lampert Mark N. Lampert By: /s/ Mark N. Lampert Chief Executive Officer Mark N. Lampert President BVF I GP LLC BVF GP HOLDINGS LLC By: /s/ Mark N. Lampert Mark N. Lampert By: /s/ Mark N. Lampert Chief Executive Officer Mark N. Lampert Chief Executive Officer BIOTECHNOLOGY VALUE FUND II, L.P. BVF PARTNERS L.P. By: BVF II GP LLC, its general partner By: BVF Inc., its general partner By: /s/ Mark N. Lampert Mark N. Lampert By: /s/ Mark N. Lampert Chief Executive Officer Mark N. Lampert President BVF II GP LLC BVF INC. By: /s/ Mark N. Lampert Mark N. Lampert By: /s/ Mark N. Lampert Chief Executive Officer Mark N. Lampert President BVF PARTNERS OS LTD. /s/ Mark N. Lampert By: BVF Partners L.P., its sole member MARK N. LAMPERT By: BVF Inc., its general partner By: /s/ Mark N. Lampert /s/ Gorjan Hrustanovic Mark N. Lampert GORJAN HRUSTANOVIC President 16 CUSIP No. 501575104 SCHEDULE A Transactions in the Securities of the Issuer During the Past Sixty Days Class of Security Securities Purchased Price ($) Date of Purchase BIOTECHNOLOGY VALUE FUND, L.P. Pre-Funded Warrants 550,425 25.2499 01/05/2024 BIOTECHNOLOGY VALUE FUND II, L.P. Pre-Funded Warrants 375,856 25.2499 01/05/2024 BIOTECHNOLOGY VALUE TRADING FUND OS LP Pre-Funded Warrants 52,733 25.2499 01/05/2024 BVF PARTNERS L.P. ( Through the Partners Managed Account ) Pre-Funded Warrants 11,085 25.2499 01/05/2024

View Full Filing

View this SC 13D/A filing on SEC EDGAR